Acasti Pharma Inc

For the period ended Mar 31, 2024. Filed Jun 21, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jun 21, 2024

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Shareholders’ Equity

Class A common shares · Additional paid-in capital · Accumulated other comprehensive loss · Accumulated deficit · Total shareholders' equity
(Expressed in thousands expect share data) · Number · Amount
$ · $ · $ · $ · $
Balance, March 31, 2023	7,435,533	258,294	13,965	(6,038)	(198,266)	67,955
Net loss and total comprehensive loss for the period	—	—	—	—	(12,853)	(12,853)
Stock-based compensation	—	—	913	—	—	913
Issuance of common shares and pre-funded warrants through private placement, net of offering costs	1,951,371	2,744	2,963	—	—	5,707
Issuance of common shares upon the exercise of stock options	12,500	—	21	—	—	21
Balance at March 31, 2024	9,399,404	261,038	17,862	(6,038)	(211,119)	61,743

Class A common shares · Additional paid-in capital · Accumulated othercomprehensive loss · Accumulated deficit · Total shareholders' equity
(Expressed in thousands expect share data) · Number · Amount
$ · $ · $ · $ · $
Balance, March 31, 2022	7,381,425	257,990	12,154	(6,037)	(155,837)	108,270
Net loss and total comprehensive loss for the period	—	—	—	—	(42,429)	(42,429)
Cumulative translation adjustment	—	—	—	(1)	—	(1)
Stock-based compensation	—	—	1,811	—	—	1,811
Net proceeds from shares issued under the at-the-market (ATM) program	54,108	304	—	—	—	304
Balance at March 31, 2023	7,435,533	258,294	13,965	(6,038)	(198,266)	67,955

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.